Digoxin is often used in the management of patients with heart failure (HF) with or without atrial fibrillation (AF). There is sound biological rationale for the use of digoxin, but the data on clinical outcomes with digoxin use in this patient population are conflicting. There is a single adequately powered randomised trial of digoxin in patients with HF in sinus rhythm. This trial showed a small but significant reduction in the rate of hospitalisation due to HF with the use of digoxin, when compared to placebo, among patients treated with ACE inhibitors and diuretics. There was no effect on mortality. When compared to placebo, among patients treated with ACE inhibitors and diuretics. There was no effect on mortality. When compared to placebo, among patients treated with ACE inhibitors and diuretics. There was no effect on mortality.

On the contrary, there are numerous secondary analyses of observational data from randomised trials which suggest that there may be an increased risk of death from using digoxin, both in patients with HF, those in AF, or both. However, observational data on digoxin use suffer from treatment bias (confounding by indication), as the sickest patients are the ones who are prescribed digoxin. Propensity matched analyses have been attempted to overcome the effect of this bias with conflicting results. However, it is likely that because the magnitude of this bias is large, no amount of statistical adjustment can yield reliable effect estimates. This highlights the need for large, randomised trials of digoxin.

REFERENCES


Pulmonary arterial hypertension (PAH) is a complex and devastating disease. According to a longitudinal United States-based registry, connective tissue disease (CTD) accounted for more than 50% of all patients with PAH, in which systemic sclerosis comprised the largest CTD-related PAH. In contrast to Western countries, systemic lupus erythematosus (SLE) is a more common CTD than systemic sclerosis in the Asia-Pacific region. A cohort study from China has shown that SLE, instead of systemic sclerosis, comprised the largest proportion of all CTD-related PAH. The prevalence of PAH in SLE is estimated at 0.5%–17.5%. The pathogenesis of PAH involves multiple mechanisms including vasculitis, in situ thrombosis to interstitial lung disease which may all increase pulmonary vascular resistance and lead to right heart failure. The leading risk factors for the development of PAH in SLE patients include Raynaud’s phenomenon, anti-U1 RNP antibody and anti-cardiolipin antibodies positivity. Since PAH is potentially life-threatening, early detection is crucial to improve the outcomes of this condition. Currently, the diagnostic algorithm for PAH in SLE patients follows that of international guidelines. Diagnosis is confirmed by right heart catheterisation. Treatments are similar to the therapeutic interventions for patients with idiopathic PAH. Since inflammatory and dysregulated immune components may play a major role in the pathogenesis of PAH in SLE, glucocorticoids and immunosuppressive therapies including cyclophosphamide are used, although the immunosuppressive therapy trials were small, uncontrolled studies only. Regular follow-up with prognostic evaluation and risk assessment should be performed and the treatment should be individualised accordingly.
Several controlled and uncontrolled trials have shown that the use of pulmonary arterial hypertension (PAH)-specific drugs might be useful in inoperable CTEPH.\textsuperscript{1,2} Ricogiguat is currently the only PAH-specific drug also approved for inoperable CTEPH.\textsuperscript{3}

Recently, balloon pulmonary angioplasty (BPA) has emerged as an alternative treatment option for patients with inoperable CTEPH or persistent PH after surgery. Several reports now support the efficacy and safety of BPA. The haemodynamic benefits were summarised in a recent review article, with an overall reduction in mean pulmonary arterial pressure of 12–21 mmHg from baseline, and a mortality rate of 0.0%–3.4% after 2–5 angioplasty sessions.\textsuperscript{4} Sustained haemodynamic improvements, almost to within the normal range, have been reported up to 3.5 years after BPA.\textsuperscript{3} Severe and fatal complications, including mostly pulmonary vessel injury, may be minimised with not only accumulation of experience but also refinements in technique. An old approach with targeting only one lobe during each session and full balloon sizing increased the incidence of complications. Approaching with undersized balloon may reduce or prevent vessel injury but is less effective in each individual segment, so several segments and lobes are targeted at one session. BPA has the potential to become a key treatment strategy for patients with inoperable CTEPH. However, the indications and limitations of BPA have not been fully established. An international registry contributed by specialised centres is needed for further investigations.

REFERENCES


Heart Asia: first published as 10.1136/heartasia-2019-apahff.30 on 24 April 2019. Downloaded from http://heartasia.bmj.com/ on September 13, 2023 by guest. Protected by copyright.

31 FABRY DISEASE IN EAST ASIA

1Alex PW Lee, 2Kevin KH Kam, 3Erik Fung, 4Josie Chow, 5Yitang Fan, 6Polakit Teekakirikul, 1Katak Wong, 1Joseph YS Chan, 2David Chan, 3Run Sheng, 1Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR; 2Department of Health, Hong Kong SAR; 3Princess Margaret Hospital, Hong Kong SAR

10.1136/heartasia-2019-apahff.31

Fabry disease (FD) is an X-linked inherited lysosomal storage disorder that results from mutations in the α-galactosidase A gene (GLA), leading to deficient α-galactosidase A (α-GalA) activity and subsequent accumulation of globotriaosylceramide (Gb3) in a variety of tissues.\textsuperscript{1} The estimated prevalence of classic FD in males ranges from 1:8000 to 1:117,000,\textsuperscript{2} likely an underestimation given its non-specific manifestations. The mutation IVS4 +919G>A (c.936 +919G>A) associated with founder effect in East Asia was first described in Taiwan.\textsuperscript{3} Left ventricular hypertrophy (LVH) is a hallmark of the later-onset cardiac variant of FD. The prevalence of FD among adult patients with LVH is unknown. In an ongoing FD screening programme from August 2017 through 2018, we measured plasma α-GalA activity using dried blood spot testing in 143 consecutive male patients with LVH (defined as maximal LV wall thickness ≥13 mm on echocardiography). Patients with low α-GalA activity underwent GLA gene sequencing analysis and endomyocardial biopsy. Four of 143 patients with LVH (2.8%) had low plasma α-GalA activity (0.4±0.2 μmol/L wb/hr; 3%–15% of the mean in normal controls). All 4 unrelated patients (aged 53–74 years) shared the same IVS4 +919G>A mutation with maximal LV wall thickness ranging from 14–29 mm. None had extracardiac manifestations but presented with hypertrophic cardiomyopathy, hypertension, heart failure, or aortic stenosis. Endomyocardial biopsy performed in one patient showed hypertrophic cardiomyocytes with sarcoplasmic vacuolisation. Our results suggest that FD should be considered as a cause of LVH in adult men even when other more usual causes of LVH are present.

REFERENCES


32 EPIDEMIOLOGY OF HEART FAILURE IN SOUTH ASIA

Ambuj Roy, All India Institute of Medical Sciences, New Delhi, India

10.1136/heartasia-2019-apahff.32

South Asia has seen rapid epidemiological transition in the last two decades with a rapid rise in cardiovascular diseases, which have emerged as the leading cause of mortality in this region. In India the leading cause of disability adjusted life years is ischaemic heart disease which has seen a 104% increase between 1990 and 2016.\textsuperscript{1} Similarly the burden of obesity, hypertension and diabetes mellitus has increased markedly over this time and with poor control rates for these risk factors leading to a fertile soil for rise in incidence of heart failure.\textsuperscript{2} In the absence of active surveillance mechanisms reliable estimates of heart failure burden is missing. However, one study estimates it to the tune of 4.6 million which is probably a severe under-estimate given the risk factor burden.\textsuperscript{3} The study of the heart failure patients in two large registries, INTER-CHF and Trivandrum Heart Failure Registry,\textsuperscript{4} revealed disturbingly high mortality rates of 23% and 31%, respectively. This was much higher than that of patients from other low and middle income countries.\textsuperscript{4} The chief driver of this mortality seems to be suboptimal medical management of these patients with a large percentage not receiving beta-blockers and renin-angiotensin aldosterone inhibitors; drugs known to improve survival. Thus, quality improvement program using guideline-directed medical therapy will go a long way in improving survival of these patients.